Synopsis: Cera Sanitaryware has seen its stock fall sharply, but Goldman Sachs’ bulk deal has brought investor attention back to the company. The story is not just about a fallen stock. It is about whether the bathroom solutions company is quietly entering a recovery phase after several weak quarters.
A bathroom solutions stock that has corrected nearly 45 percent from its all time highs is back in focus after a large institutional investor entered the stock. The company has been dealing with weak retail demand, pressure on margins, higher input costs and uneven consumption trends.
Cera Sanitaryware Limited witnessed a bulk deal on June 8, 2026, where Goldman Sachs Funds, through Goldman Sachs India Equity Portfolio, purchased 1.18 lakh shares of the company, representing around 0.9 percent stake.
The transaction was valued at nearly Rs. 64.92 crore, with shares bought at Rs. 5,480 each. For a stock that has already crashed sharply, this raises a simple question for investors: is Goldman Sachs seeing something that the broader market has ignored?
Why The Stock Has Been Under Pressure
The weakness in Cera Sanitaryware has not come from one single issue. The company has been facing a mix of slow retail demand, input cost pressure and margin compression.
In Q2FY26, management clearly said that the demand environment remained subdued, particularly on the retail side. Revenue from operations stood at Rs. 488 crore, almost flat compared with Rs. 490 crore in Q2FY25. EBITDA also declined from Rs. 70 crore to Rs. 67 crore, while EBITDA margin slipped from 14.2 percent to 13.8 percent.
The pressure became more visible in Q3FY26. Revenue improved to Rs. 499 crore from Rs. 449 crore in Q3FY25, showing 11.1 percent growth, but EBITDA fell to Rs. 51 crore from Rs. 59 crore. EBITDA margin dropped sharply to 10.2 percent. Management called this a quarter affected by one-off phasing impact.
The main reasons were higher input costs, especially brass, continued trade discounts and investment expenses linked to Senator and Polipluz. In Q4FY26, EBITDA margin improved to 15.2 percent from 10.2 percent in Q3, but it was still lower than 18.3 percent in Q4FY25. This means the company has recovered from the weakest margin quarter, but it has not yet fully returned to its earlier comfort zone.
The Recovery Is Starting To Show
The important part is that Cera’s demand picture improved in the second half of FY26. After a soft Q2, the company reported 11.1 percent revenue growth in Q3FY26 and 11.4 percent revenue growth in Q4FY26. Management said Q4 performance built on the early recovery signs seen from Q3 and reinforced its confidence that demand conditions were gradually improving.
This is important because the recovery is being led by core categories. In Q4FY26, sanitaryware and faucetware contributed 46 percent and 43 percent of revenue respectively. Together, these two core categories accounted for 89 percent of total revenue. Sanitaryware revenue grew 10.7 percent year-on-year, faucetware grew 24.3 percent, wellness grew 31.2 percent, while tiles declined 8.3 percent.
The Q4 growth was also not just a pricing story. Management said the quarter’s growth was largely volume-driven, with volume growth of around 12 percent and product mix improvement of 3 to 4 percent, partly offset by adverse pricing impact from discounts. This matters because a volume-led recovery is usually healthier than growth driven only by price hikes.
Margins Still Need Repair
Even though demand is improving, Cera’s biggest near-term challenge remains margins. Brass prices have increased significantly, and faucetware is directly exposed to brass costs. Management said brass prices had risen around 29 to 30 percent over the last year. To offset this, Cera implemented price hikes across sanitaryware and faucetware.
In Q4FY26, the company took calibrated price revisions of 4 percent in sanitaryware and 11 percent in faucetware towards the later part of the quarter. Later in the earnings call, management explained that over two months, effective price increases were around 12 percent in sanitaryware and 16 percent in faucetware. However, these price hikes were immediately applicable mainly to retail sales. Project pricing takes longer to reflect because project orders are usually booked for a fixed period.
This means margin recovery may not happen instantly. Retail should see the benefit earlier, while project business may take longer to absorb the new pricing. Management also said discount control will be an important lever. In simple words, Cera has already raised prices, but the real margin repair depends on whether the company can reduce trade discounts as demand improves.
The comfort is that Q4 margin has already improved from Q3. Management said that if the current demand trend continues, the company should be able to sustain EBITDA margins around 14 to 15 percent. Earlier, management had also indicated that margins of 16 to 17 percent could become more likely in the second half of FY27 if growth sustains and one-off impacts do not repeat.
What Cera Is Doing Differently
Cera is not only waiting for demand to recover. The company is trying to build a more segmented brand structure. The core Cera brand remains the main driver of volumes, but the company is also building Senator for the premium segment and Polipluz for the value segment.
Senator is targeted at a higher-end customer base that Cera was not fully addressing earlier. Management said the product profile, dealer network, showroom format and consumer experience under Senator are different from the existing Cera portfolio. By FY26, Cera had 40 Senator flagship stores operational and is targeting 60 stores by the next financial year.
Polipluz is focused on the value segment, where the unorganized market still has a large share. In Q2FY26, Polipluz was distributed through 38 distributors and 650 dealers, with a target of 100 distributors and 2,000 dealers by March 2026. By FY26, it had already reached 102 distributors and 1,120 dealers, with a target to expand to 200 distributors and 2,000 dealers by the end of FY27.
These initiatives are still in the investment and brand-building phase, so investors should not expect immediate large profits from them. But they show why Cera is trying to widen its market. Senator can help it move higher in premium bathrooms, while Polipluz can help it attack value-focused markets where branded penetration is still lower.
The company is also becoming more data-driven. Its Dealer Management System has already onboarded more than 200 dealers in Q2FY26. This gives the company better visibility on secondary sales, dealer inventory and retail movement. Its retailer loyalty program, with more than 28,000 enrolled retailers, is also planned to become automated once the system stabilizes.
Why Goldman May Be Interested
The possible attraction for Goldman Sachs could be that Cera is not a broken company, even though the stock has corrected sharply. The company still has a trusted brand built over four decades, a pan-India distribution network, strong positioning across sanitaryware and bathware, and a portfolio that covers value to premium segments.
The balance sheet is another key strength. As of March 31, 2026, Cera had cash and cash equivalents of Rs. 853 crore along with a debt free balance sheet. FY26 revenue stood at Rs. 2,050 crore, compared with Rs. 1,915 crore in FY25, while EBITDA stood at Rs. 322 crore and PAT stood at Rs. 204 crore.
Yes, FY26 profitability declined. PAT fell from Rs. 246 crore in FY25 to Rs. 204 crore in FY26, while EBITDA declined from Rs. 353 crore to Rs. 322 crore. ROCE also moderated from 21 percent in FY25 to 18 percent in FY26, and ROE declined from 18 percent to 14 percent. But even after this fall, the company remains profitable, debt-free and cash-rich.
This is probably the key difference. The market may be focusing on the 45 percent correction and margin pressure, while a long-term institutional investor like Goldman may be looking at brand strength, recovery signs, cash reserves, capacity expansion and the possibility of margin normalization.
The Risks Are Still Real
Cera is not without risks. Retail demand is still uneven, input costs remain volatile and trade discounts need to be controlled. Brass and energy costs can continue to affect margins. The company also has meaningful outsourcing exposure, especially in sanitaryware. In Q4FY26, outsourcing was 60 percent for sanitaryware and 46 percent for faucetware, with sanitaryware outsourcing mostly from Morbi.
The Morbi region has faced gas availability and price-related disruptions. Cera said it has adequate inventory to manage a large portion of Q1 and part of Q2, and it has started internalizing certain products earlier sourced from Morbi. But if supply disruptions persist longer than expected, execution can still become a challenge.
Another risk is that Senator and Polipluz are still in the build-up phase. These brands require marketing, distribution and execution investment. Management spent around Rs. 49 crore on marketing and publicity in FY26 and expects this to increase in FY27. If these brands take longer to scale, costs may come before meaningful revenue contribution.
Final View
Goldman Sachs buying into Cera Sanitaryware does not automatically mean the stock will recover immediately. But it does make the story interesting because the business is showing early signs of improvement after a weak phase. Revenue growth has returned in Q3 and Q4, core categories are improving, faucetware demand remains strong, price hikes have been taken, and margins have already bounced back from the Q3 low.
At the same time, the company still has to prove that it can sustain growth, control discounts, manage input costs and scale Senator and Polipluz without hurting profitability. The stock may have crashed 45 percent, but the business is not financially stressed. It remains debt-free, cash-rich and profitable, with strong brand recall and a large distribution base.
In simple words, Goldman Sachs may not be buying a perfect company. It may be buying a recovery stock where the bad news is already visible, but the improvement has only started showing in the numbers.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
